Renal Disease Market Research Report - Forecast till 2027

Renal Disease Market: Information by Disease Type (Chronic Kidney Disease and End-Stage Renal Disease (ESRD)), by Treatment Type (Dialysis, Medication and Kidney Transplantation), by End User (Dialysis Centers, Hospital & Clinics, and Research and Academic Institutes) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/2289-CR | February 2021 | Region: Global | 157 Pages         

1 Executive Summary

2 Market Introduction

2.1 Scope of Study 17

2.2 Research Objective 17

2.3 List of Assumptions 18

3 Research Methodology

3.1 Research Process 20

3.2 Primary Research 21

3.3 Secondary Research 21

3.4 Market Size Estimation 23

4 Market Dynamics

4.1 Introduction 24

4.2 Drivers 25

4.2.1 Rising Prevalence of Kidney Disease 25

4.2.1 Growing Prevalence of Diabetes and Hypertension 25

4.2.2 Rapid Growth in the Geriatric Population 25

4.3 Restraints 26

4.3.1 Rising Healthcare Cost 26

4.3.2 Stringent Regulatory Policies 26

4.4 Opportunities 26

4.4.1 Expansion in Developing Economies 26

4.5 Market Trends 26

4.5.1 Artificial Intelligence (AI) for Managing and Diagnosis of Chronic Kidney Disease (CKD) 26

4.6 Macroeconomic Indicators 27

5 Market Factor Analysis

5.1 Porter’s Five Forces Analysis 28

5.1.1 Bargaining Power of Suppliers 28

5.1.2 Bargaining Power of Buyers 29

5.1.3 Threat of New Entrants 29

5.1.4 Threat of Substitutes 29

5.1.5 Intensity of Rivalry 29

5.2 Value Chain Analysis 30

5.2.1 R&D and Designing 30

5.2.2 Manufacturing 30

5.2.3 Distribution and Sales 30

5.2.4 Post-Sales Services 31

5.3 Pricing Analysis 31

5.4 Investment Opportunities 32

6 Renal Disease Market, By Disease Type

6.1 Overview 33

6.2 Chronic Kidney Disease 34

6.3 End-Stage Renal Disease (ESRD) 35

7 Renal Disease Market, By Treatment Type

7.1 Overview 36

7.2 Dialysis 37

7.3 Medication 38

7.4 Kidney Transplantation 40

8 Renal Disease Market, By End User

8.1 Overview 41

8.2 Dialysis Centres 42

8.3 Hospital & Clinics 43

8.4 Research and Academic Institutes 44

9 Global Renal Disease Market, by Region

9.1 Overview 45

9.2 Americas 47

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.2.1 North America 50

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.2.1.1 US 53

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.2.1.2 Canada 56

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.2.2 Latin America 58

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3 Europe 61

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1 Western Europe 64

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1.1 Germany 68

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1.2 France 70

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1.3 UK 73

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1.4 Italy 75

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1.5 Spain 78

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.1.6 Rest of Western Europe 80

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.3.2 Eastern Europe 83

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4 Asia-Pacific 86

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4.1 Japan 89

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4.2 China 92

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4.3 India 94

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4.4 South Korea 97

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4.5 Australia 99

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.4.6 Rest of Asia-Pacific 102

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.5 Middle East & Africa 105

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.5.1 Middle East 108

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

9.5.2 Africa 111

Renal Disease Market, By Disease Type

Renal Disease Market, By Treatment Type

Renal Disease Market, By End User

10 Competitive Landscape

10.1 Introduction 114

11 Company Profiles

11.1 Abbott 116

11.1.1 Company Overview 116

11.1.2 Financial Overview 116

11.1.3 Products/Services Offered 117

11.1.4 Key Developments 117

11.1.5 SWOT Analysis 117

11.1.6 Key Strategies 117

11.2 Amgen Inc. 118

11.2.1 Company Overview 118

11.2.2 Financial Overview 118

11.2.3 Products/Services Offered 119

11.2.4 Key Developments 119

11.2.5 SWOT Analysis 120

11.2.6 Key Strategies 120

11.3 AstraZeneca 121

11.3.1 Company Overview 121

11.3.2 Financial Overview 121

11.3.3 Products/Services Offered 122

11.3.4 Key Developments 122

11.3.5 SWOT Analysis 123

11.3.6 Key Strategies 123

11.4 Bristol-Myers Squibb Company 124

11.4.1 Company Overview 124

11.4.2 Financial Overview 124

11.4.3 Products/Services Offered 124

11.4.4 Key Developments 125

11.4.5 SWOT Analysis 125

11.4.6 Key Strategies 125

11.5 F. Hoffmann-La Roche Ltd 126

11.5.1 Company Overview 126

11.5.2 Financial Overview 126

11.5.3 Products/Services Offered 127

11.5.4 Key Developments 127

11.5.5 SWOT Analysis 127

11.5.6 Key Strategies 127

11.6 Fresenius Medical Care AG & Co. KGaA 128

11.6.1 Company Overview 128

11.6.2 Financial Overview 128

11.6.3 Products/Services Offered 129

11.6.4 Key Developments 129

11.6.5 SWOT Analysis 130

11.6.6 Key Strategies 130

11.7 GlaxoSmithKline PLC 131

11.7.1 Company Overview 131

11.7.2 Financial Overview 131

11.7.3 Products/Services Offered 131

11.7.4 Key Developments 132

11.7.5 SWOT Analysis 132

11.7.6 Key Strategies 132

11.8 Keryx Biopharmaceuticals, Inc. 133

11.8.1 Company Overview 133

11.8.2 Financial Overview 133

11.8.3 Products/Services Offered 133

11.8.4 Key Developments 134

11.8.5 SWOT Analysis 134

11.8.6 Key Strategies 134

11.9 Kissei Pharmaceutical Co., Ltd 135

11.9.1 Company Overview 135

11.9.2 Financial Overview 135

11.9.3 Products/Services Offered 135

11.9.4 Key Developments 136

11.9.5 SWOT Analysis 136

11.9.6 Key Strategies 136

11.10 Novartis AG 137

11.10.1 Company Overview 137

11.10.2 Financial Overview 137

11.10.3 Products/Services Offered 137

11.10.4 Key Developments 138

11.10.5 SWOT Analysis 138

11.10.6 Key Strategies 138

11.11 Pfizer Inc. 139

11.11.1 Company Overview 139

11.11.2 Financial Overview 139

11.11.3 Products/Services Offered 140

11.11.4 Key Developments 140

11.11.5 SWOT Analysis 140

11.11.6 Key Strategies 140

11.12 Sanofi SA 141

11.12.1 Company Overview 141

11.12.2 Financial Overview 141

11.12.3 Products/Services Offered 142

11.12.4 Key Developments 142

11.12.5 SWOT Analysis 142

11.12.6 Key Strategies 142

11.13 Teva Pharmaceutical Industries Ltd 143

11.13.1 Company Overview 143

11.13.2 Financial Overview 143

11.13.3 Products/Services Offered 143

11.13.4 Key Developments 144

11.13.5 SWOT Analysis 144

11.13.6 Key Strategies 144

12 Appendix

12.1 Discussion Blue Print 145

13 List of Tables

TABLE 1 MARKET SYNOPSIS 16

TABLE 2 LIST OF ASSUMPTIONS 18

TABLE 3 PRIMARY INTERVIEWS 21

TABLE 4 PRICING RANGE OF KIDNEY TREATMENT (ANNUAL COST) 31

TABLE 5 GLOBAL RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 33

TABLE 6 GLOBAL RENAL DISEASE MARKET, FOR CHRONIC KIDNEY DISEASE, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 7 GLOBAL RENAL DISEASE MARKET, FOR END-STAGE RENAL DISEASE (ESRD), BY REGION, 2020–2027 (USD MILLION) 35

TABLE 8 GLOBAL RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 36

TABLE 9 GLOBAL RENAL DISEASE MARKET, FOR DIALYSIS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 10 GLOBAL RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 38

TABLE 11 GLOBAL RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 39

TABLE 12 GLOBAL RENAL DISEASE MARKET, FOR MEDICATION, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 13 GLOBAL RENAL DISEASE MARKET, FOR KIDNEY TRANSPLANTATION, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 14 GLOBAL RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 41

TABLE 15 GLOBAL RENAL DISEASE MARKET, FOR DIALYSIS CENTRES, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 16 GLOBAL RENAL DISEASE MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 17 GLOBAL RENAL DISEASE MARKET, FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 18 GLOBAL RENAL DISEASE MARKET, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 19 AMERICAS: RENAL DISEASE MARKET, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 20 AMERICAS: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 48

TABLE 21 AMERICAS: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 48

TABLE 22 AMERICAS: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 49

TABLE 23 AMERICAS: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 49

TABLE 24 AMERICAS: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 50

TABLE 25 NORTH AMERICA: RENAL DISEASE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50

TABLE 26 NORTH AMERICA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 51

TABLE 27 NORTH AMERICA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 51

TABLE 28 NORTH AMERICA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 29 NORTH AMERICA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 30 NORTH AMERICA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 31 US: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 53

TABLE 32 US: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 54

TABLE 33 US: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 34 US: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 35 US: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 55

TABLE 36 CANADA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 56

TABLE 37 CANADA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 56

TABLE 38 CANADA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 39 CANADA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 40 CANADA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 58

TABLE 41 LATIN AMERICA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 58

TABLE 42 LATIN AMERICA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 59

TABLE 43 LATIN AMERICA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 44 LATIN AMERICA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 45 LATIN AMERICA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 46 EUROPE: RENAL DISEASE MARKET, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 47 EUROPE: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 62

TABLE 48 EUROPE: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 62

TABLE 49 EUROPE: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 50 EUROPE: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 51 EUROPE: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 52 WESTERN EUROPE: RENAL DISEASE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 53 WESTERN EUROPE: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 65

TABLE 54 WESTERN EUROPE: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 66

TABLE 55 WESTERN EUROPE: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 56 WESTERN EUROPE: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 57 WESTERN EUROPE: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 58 GERMANY: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 68

TABLE 59 GERMANY: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 68

TABLE 60 GERMANY: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 61 GERMANY: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 62 GERMANY: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 63 FRANCE: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 70

TABLE 64 FRANCE: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 71

TABLE 65 FRANCE: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 66 FRANCE: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 67 FRANCE: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 68 UK: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 73

TABLE 69 UK: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 73

TABLE 70 UK: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 71 UK: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 72 UK: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 73 ITALY: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 75

TABLE 74 ITALY: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 76

TABLE 75 ITALY: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 76 ITALY: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 77 ITALY: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 77

TABLE 78 SPAIN: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 78

TABLE 79 SPAIN: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 78

TABLE 80 SPAIN: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 81 SPAIN: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 82 SPAIN: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 83 REST OF WESTERN EUROPE: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 80

TABLE 84 REST OF WESTERN EUROPE: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 81

TABLE 85 REST OF WESTERN EUROPE: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 86 REST OF WESTERN EUROPE: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 87 REST OF WESTERN EUROPE: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 88 EASTERN EUROPE: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 83

TABLE 89 EASTERN EUROPE: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 83

TABLE 90 EASTERN EUROPE: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 91 EASTERN EUROPE: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 92 EASTERN EUROPE: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 93 ASIA-PACIFIC: RENAL DISEASE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86

TABLE 94 ASIA-PACIFIC: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 87

TABLE 95 ASIA-PACIFIC: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 87

TABLE 96 ASIA-PACIFIC: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 97 ASIA-PACIFIC: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 98 ASIA-PACIFIC: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 99 JAPAN: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 89

TABLE 100 JAPAN: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 90

TABLE 101 JAPAN: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 102 JAPAN: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 103 JAPAN: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 91

TABLE 104 CHINA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 92

TABLE 105 CHINA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 92

TABLE 106 CHINA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 107 CHINA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 108 CHINA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 94

TABLE 109 INDIA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 94

TABLE 110 INDIA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 95

TABLE 111 INDIA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 112 INDIA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 113 INDIA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 96

TABLE 114 SOUTH KOREA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 97

TABLE 115 SOUTH KOREA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 97

TABLE 116 SOUTH KOREA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 117 SOUTH KOREA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 118 SOUTH KOREA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 119 AUSTRALIA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 99

TABLE 120 AUSTRALIA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 100

TABLE 121 AUSTRALIA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 100

TABLE 122 AUSTRALIA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 123 AUSTRALIA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 101

TABLE 124 REST OF ASIA-PACIFIC: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 102

TABLE 125 REST OF ASIA-PACIFIC: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 102

TABLE 126 REST OF ASIA-PACIFIC: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 127 REST OF ASIA-PACIFIC: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 128 REST OF ASIA-PACIFIC: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 104

TABLE 129 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET, BY REGION, 2020–2027 (USD MILLION) 105

TABLE 130 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 106

TABLE 131 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 106

TABLE 132 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 133 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 134 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 108

TABLE 135 MIDDLE EAST: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 108

TABLE 136 MIDDLE EAST: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 109

TABLE 137 MIDDLE EAST: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 109

TABLE 138 MIDDLE EAST: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 110

TABLE 139 MIDDLE EAST: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 110

TABLE 140 AFRICA: RENAL DISEASE MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 111

TABLE 141 AFRICA: RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020–2027 (USD MILLION) 111

TABLE 142 AFRICA: RENAL DISEASE MARKET, FOR MEDICATION, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 143 AFRICA: RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 144 AFRICA: RENAL DISEASE MARKET, BY END USER, 2020–2027 (USD MILLION) 113

TABLE 145 TOP MANUFACTURERS IN THE GLOBAL RENAL DISEASE MARKET 115

14 List of Figures

FIGURE 1 GLOBAL RENAL DISEASE MARKET: STRUCTURE 18

FIGURE 2 RESEARCH PROCESS 20

FIGURE 3 TOP-DOWN AND BOTTOM-UP APPROACHES 23

FIGURE 4 VALUE CHAIN 30

FIGURE 5 GLOBAL RENAL DISEASE MARKET SHARE, BY DISEASE TYPE, 2020 (%) 33

FIGURE 6 GLOBAL RENAL DISEASE MARKET, BY DISEASE TYPE, 2020 & 2027 (USD MILLION) 34

FIGURE 7 GLOBAL RENAL DISEASE MARKET SHARE, BY TREATMENT TYPE, 2020 (%) 36

FIGURE 8 GLOBAL RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020 & 2027 (USD MILLION) 37

FIGURE 9 GLOBAL RENAL DISEASE MARKET SHARE, BY END USER, 2020 (%) 42

FIGURE 10 GLOBAL RENAL DISEASE MARKET, BY END USER, 2020 & 2027 (USD MILLION) 42

FIGURE 11 GLOBAL RENAL DISEASE MARKET SHARE, BY REGION, 2020 (%) 46

FIGURE 12 GLOBAL RENAL DISEASE MARKET, BY REGION, 2020 & 2027 (USD MILLION) 46

FIGURE 13 AMERICAS: RENAL DISEASE MARKET SHARE, BY REGION, 2020 (%) 48

FIGURE 14 EUROPE: RENAL DISEASE MARKET SHARE, BY REGION, 2020 (%) 62

FIGURE 15 WESTERN EUROPE: RENAL DISEASE MARKET SHARE, BY COUNTRY, 2020 (%) 65

FIGURE 16 ASIA-PACIFIC: RENAL DISEASE MARKET SHARE, BY COUNTRY, 2020 (%) 87

FIGURE 17 MIDDLE EAST & AFRICA: RENAL DISEASE MARKET SHARE, BY REGION, 2020 (%) 105

Renal Disease Market Speak to Analyst Request a Free Sample

Renal Disease Market Overview


By 2023, a CAGR of 6.32% is expected to reach USD 133,451.06 million for the Renal Disease Market size. When the kidney cannot function properly, this renal disease occurs. Hence, it is also known as kidney disease. Depending upon the different numerous conditions, different types of symptoms, and signs, different types of kidney diseases are formed. 


In this vast population, most of the people are suffering from renal disease, diabetes, and hypertension. The growth of geriatric people is expected to increases the chronic kidney disease market growth. Apart, the healthcare cost and stringent regulatory policies are going to be increasing.


COVID-19 Analysis:


COVID-19 pandemic has everyone’s life in different ways. Due to the government regulations and lockdowns, people stayed in the home itself, and hence the demand for home dialysis increases. Most of the affected people of COVID-19 are people suffering from diabetes and ESRD compared to healthy people. The condition with reduced kidney function leads to chronic kidney disease which may lead to end-stage renal disease (ESRD). 


Worldwide, all countries are taking necessary steps to ensure the safety of the patients amid the crisis. Additionally, the government issued the guidelines and Interim Additional Guidance for Infection Prevention and Control (IPC) recommendations for the patients who are suspected and confirmed of the coronavirus disease.


Market Dynamics:


Driver:


Diagnosis of Blood Test for high growth over the forecast period


A blood test is a major test for the diagnosis of kidney disease which shows detailed information about kidneys working conditions. Due to the increase of CKD (Chronic Kidney Disease), the demand for blood tests is expected to increase. Moreover, the ESRD (End-Stage Renal Disease) is also increasing at a significant rate.


 In 2017, it is recorded that 697.5 million people with CKD struggle. After causing CKD, it may develop and lead to ESRD which tends to kidney failure. In Singapore, from 2007 to 2017 the prevalence of CKD increases from 12% to 17% and is further expected to increase by approximately 24% by 2035.  Due to the rise of chronic kidney disease, the market is expected to be high over the forecast period. An increasing number of patients with hypertension and diabetes, high prevalence of ESRD, and rapid growth in the geriatric population are major drivers of the market.


Restraint:


Rise of Healthcare cost and stringent regulatory policies


By increasing the cost of the healthcare sector and stringent regulatory policies are the restraints of the market growth. By reducing the cost of the healthcare sector, it may be expected to increase the growth of renal disease treatment.


Opportunities:


Expansion in Developing Economies


The developing and developed countries launched advanced technological products in the market to reduce the increase in renal failures. This new expansion increases the end-stage renal disease market growth.


Challenge:


Reduction of the cost over the healthcare sector is the major challenge of the end-stage market growth.


Technology Analysis


The technologically advanced products like low maintenance dialysis equipment for diagnosis of Chronic Kidney Disease and artificial kidney helps to the growth of the end-stage renal disease market.


Study Objectives -



  • To provide detailed information about the renal disease market structure along with various forecast segments and sub-segments.

  • To provide the factors that affecting the end-stage renal disease market growth.

  • To analyze the renal disease market-based porter’s five force analysis, etc.

  • To provide history and forecast revenue segments for the four main geographic countries

  • To provide the country-level analysis of the current renal disease market size and future prospective

  • To provide country-level analysis of the end-stage market growth by region, application, treatment

  • To provide a strategic profile of the key players in the market, analyze their core competencies, and draw a landscape of the renal disease market growth.

  • To track and analyze new product developments, strategic alliances, and research in the global renal disease market.


Segment Overview:


Globally, Renal disease stages have been segmented into two types of diseases like chronic kidney disease and end-stage renal disease.


Based on Treatment Type


The renal disease market is segmented into dialysis, medication, and kidney transplantation. Further dialysis is segmented into peritoneal dialysis, hemodialysis, and wearable artificial kidney for renal disease treatment.


Based on end-users


The renal disease market is segmented into dialysis centers, hospitals &clinics, research, and academic institutes.


Based on Region


Based on the region, the renal disease market is divided into four regions-America, Europe, Asia-Pacific, and the Middle East & Africa. Out of these, America is expected to be the highest market share among the others. Europe is expected to be the second-largest and Asia-Pacific is to be the fastest-growing region in the global market over the forecast period. 


Regional Analysis -


Based on the region, the renal disease market is divided into four main regions- America, Europe, Asia-Pacific, and the Middle East & Africa.


Due to the increasing prevalence of renal disease causes to the geriatric population and the high availability of advanced features in North America, America is expected to the largest market share in the renal disease market. Europe is expected to be the second-largest share of the renal disease market for its high awareness of renal diseases, the government extended recommendations for dialysis, and the elderly population growth. In Europe, there is a rise in demand for diagnostic tests. In 2015, 10% of people are affected by CKD.


Due to the presence of developing economies like India, China, and South Korea, Asia-Pacific is expected to be the fastest-growing region in the market. These countries are highly demandable for the outsourcing of drug manufacturing, clinical trials, and pathology testing. Due to the high prevalence of renal disease in Saudi Arabia, Kuwait, and the UAE, the Middle East & Africa are expected to grow in the market.


Competitive Landscape


The prominent key players in the renal disease market are as follows:



  • Abbott (US)

  • Amgen Inc (US)

  • AstraZeneca (US)

  • Bristol-Myers Squibb Company (US)

  • Hoffmann- La Roche Ltd (Switzerland)

  • Fresenius Medical Care AG & Co., Ltd (Japan)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • Sanofi SA (France) and

  • Teva Pharmaceutical Industries Ltd (Israel)


These key players are focussing on the launch of new developments, innovation, mergers, and acquisitions. Fresenius Medical Care is one of the leading companies that introduce new developments with advanced features.


Recent Developments



  • In October 2016, Teva acquired Anda, Inc. which is a leading distributor of generic pharmaceuticals.

  • In June 2017, Sanofi to strengthen its pharmaceutical business in Morocco and other African countries, Sanofi signed with a Europharma in Morocco.

  • In May 2015, Fresenius introduced a new therapy system multiFiltratePRO which is continuous renal replacement therapy (CRRT) that is used for the treatment of acute kidney failure.

  • In October 2019, Fresenius Medical Care has designated with U.S FDA for its new hemodialysis machine which is used to stop blood clotting without any use of medication. 


Report Overview:


The full report is inclusive of the following:



  • Market Overview

  • COVID-19 Analysis

  • Market Dynamics

  • Technology Analysis

  • Study Objectives

  • Segment Overview

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments

  • Segmentation Table

  • FAQs


Segmentation Table


The research in the segmentation of the renal disease market is done based on treatment, end-users, and region.


By Disease Type


Chronic Kidney Disease, end-stage renal disease


By Treatment Type


Dialysis, medication, and kidney transplantation


By end-user


Dialysis centers, hospitals & clinics, research, and academic institutes


By Region


America, Europe, Asia-Pacific, and Middle-East & Africa



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 133,451.06 million
  • 2027: Significant Value
  •   CAGR   6.32% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Disease Type, Treatment Type, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott (US), Amgen Inc (US), AstraZeneca (US), Bristol-Myers Squibb Company (US), Hoffmann- La Roche Ltd (Switzerland), Fresenius Medical Care AG & Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi SA (France) and Teva Pharmaceutical Industries Ltd (Israel)
      Key Market Opportunities   Expansion in Developing Economies
      Key Market Drivers   Diagnosis of Blood Test for high growth


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Renal disease market projected to grow at approximately 6.32% CAGR during the assessment period (2020-2027).

    The valuation of the renal disease market is estimated to increase to USD 133,451.06 MN by the end of 2023.

    Growth in the prevalence of kidney diseases and the rising government funding for R&D & initiatives to spread the awareness, are major tailwinds pushing the growth of the global renal disease market.

    North America holds the largest share in the global renal disease market, followed by Europe and the Asia Pacific, respectively.

    Amgen Inc. (US), AstraZeneca (US), Abbott (US), Bristol-Myers Squibb Company (US), Fresenius Medical Care AG & Co. KGaA (UK), Teva Pharmaceutical Industries Ltd (Israel), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Kissei Pharmaceutical Co., Ltd (Japan), Keryx Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), and Sanofi SA (France), are some of the top players operating in the global renal disease market.